The Biomedical Catalyst will return later this month! In Round 1, UK registered SMEs can apply for a share of £15 million to develop innovative health or healthcare-focused products, technologies and processes.
Scope
Projects can focus on any health or healthcare challenge. They can include a range of activities, such as:
- experimental evaluation (at laboratory scale)
- use of in vitro and in vivo models to evaluate proof of concept or safety
- exploring potential production mechanisms
- prototyping
- product development planning
- intellectual property protection
- a demonstration of clinical utility and effectiveness
- a demonstration of safety and efficacy (including phase 1 and 2 clinical trials)
- regulatory planning
As this is the Industry-led R&D stream of the Biomedical Catalyst programme, applicants must also demonstrate existing evidence of commercial and technical feasibility.
Eligibility
All projects must meet the following eligibility criteria:
- have total project costs between £150,000 and £4 million, not exceeding a grant request of £2 million
- have at least 50% of the total project costs shared by the SMEs, if collaborative
- start before 1 December 2022 and end before 30 November 2025
- last between 6 months and 36 months
- carry out all project work in the UK and intend to exploit the results from or in the UK
To lead a project or work alone, your organisation must be a UK registered SME. You can work in collaboration with other organisations, including businesses of any size, academic institutions, charities, not-for-profits, public sector organisations, or research and technology organisations. They must also be registered in the UK.
More Information
Round 1 of the Biomedical Catalyst is open from 28th March until 25th May. For more information, please visit the competition page or join the online briefing event on 5th April.
RedKnight has a strong track record of securing funding for life science companies. If you would like to discuss working together, please contact us to arrange a free consultation.